579 related articles for article (PubMed ID: 37452934)
21. Pathologic and molecular aspects of anaplasia in circumscribed gliomas and glioneuronal tumors.
Pujadas E; Chen L; Rodriguez FJ
Brain Tumor Pathol; 2019 Apr; 36(2):40-51. PubMed ID: 30859342
[TBL] [Abstract][Full Text] [Related]
22. Newly codified glial neoplasms of the 2007 WHO Classification of Tumours of the Central Nervous System: angiocentric glioma, pilomyxoid astrocytoma and pituicytoma.
Brat DJ; Scheithauer BW; Fuller GN; Tihan T
Brain Pathol; 2007 Jul; 17(3):319-24. PubMed ID: 17598825
[TBL] [Abstract][Full Text] [Related]
23. Supratentorial high-grade astrocytoma and diffuse brainstem glioma: two challenges for the pediatric oncologist.
Broniscer A; Gajjar A
Oncologist; 2004; 9(2):197-206. PubMed ID: 15047924
[TBL] [Abstract][Full Text] [Related]
24. Metachronous, multicentric glioma of pilocytic astrocytoma with oligodendroglioma-like component and oligodendroglioma through distinct genetic aberrations.
Kanoke A; Kanamori M; Kumabe T; Saito R; Watanabe M; Tominaga T
J Neurosurg; 2013 Apr; 118(4):854-8. PubMed ID: 23082883
[TBL] [Abstract][Full Text] [Related]
25. [Histological and molecular classification of gliomas].
Figarella-Branger D; Colin C; Coulibaly B; Quilichini B; Maues De Paula A; Fernandez C; Bouvier C
Rev Neurol (Paris); 2008; 164(6-7):505-15. PubMed ID: 18565348
[TBL] [Abstract][Full Text] [Related]
26. Leat-associated seizures the possible role of EAAT2, pyruvate carboxylase and glutamine synthetase.
Buccoliero AM; Caporalini C; Moscardi S; Cetica V; Mei D; Conti V; Nozzoli F; Bonaudo C; Battista F; Giordano F; Mura R; Spacca B; Mussa F; D'Onofrio V; Guerrini R; Genitori L; Scagnet M
Epilepsy Res; 2024 Jan; 199():107258. PubMed ID: 38086219
[TBL] [Abstract][Full Text] [Related]
27. Malignant brainstem tumors in children, excluding diffuse intrinsic pontine gliomas.
Klimo P; Nesvick CL; Broniscer A; Orr BA; Choudhri AF
J Neurosurg Pediatr; 2016 Jan; 17(1):57-65. PubMed ID: 26474099
[TBL] [Abstract][Full Text] [Related]
28. Magnetic resonance perfusion for differentiating low-grade from high-grade gliomas at first presentation.
Abrigo JM; Fountain DM; Provenzale JM; Law EK; Kwong JS; Hart MG; Tam WWS
Cochrane Database Syst Rev; 2018 Jan; 1(1):CD011551. PubMed ID: 29357120
[TBL] [Abstract][Full Text] [Related]
29. Molecular profiling of pre- and post-treatment pediatric high-grade astrocytomas reveals acquired increased tumor mutation burden in a subset of recurrences.
Wood MD; Beadling C; Neff T; Moore S; Harrington CA; Baird L; Corless C
Acta Neuropathol Commun; 2023 Sep; 11(1):143. PubMed ID: 37670377
[TBL] [Abstract][Full Text] [Related]
30. BRAF V600E-mutated diffuse glioma in an adult patient: a case report and review.
Suzuki Y; Takahashi-Fujigasaki J; Akasaki Y; Matsushima S; Mori R; Karagiozov K; Joki T; Ikeuchi S; Ikegami M; Manome Y; Murayama Y
Brain Tumor Pathol; 2016 Jan; 33(1):40-9. PubMed ID: 26445861
[TBL] [Abstract][Full Text] [Related]
31. Pleomorphic xanthoastrocytoma: DNA flow cytometry and outcome analysis of 12 patients.
Rostomily RC; Hoyt JW; Berger MS; Kros JM; Alvord EC; Wilkins P; Rabinovitch P
Cancer; 1997 Dec; 80(11):2141-50. PubMed ID: 9392337
[TBL] [Abstract][Full Text] [Related]
32. SEOM-GEINO clinical guidelines for high-grade gliomas of adulthood (2022).
Segura PP; Quintela NV; García MM; Del Barco Berrón S; Sarrió RG; Gómez JG; Castaño AG; Martín LMN; Rubio OG; Losada EP
Clin Transl Oncol; 2023 Sep; 25(9):2634-2646. PubMed ID: 37540408
[TBL] [Abstract][Full Text] [Related]
33. BRAF Inhibition in
Kaley T; Touat M; Subbiah V; Hollebecque A; Rodon J; Lockhart AC; Keedy V; Bielle F; Hofheinz RD; Joly F; Blay JY; Chau I; Puzanov I; Raje NS; Wolf J; DeAngelis LM; Makrutzki M; Riehl T; Pitcher B; Baselga J; Hyman DM
J Clin Oncol; 2018 Dec; 36(35):3477-3484. PubMed ID: 30351999
[TBL] [Abstract][Full Text] [Related]
34. A case of high-grade astrocytoma with BRAF and ATRX mutations following a long-standing course over two decades.
Nakata S; Horiguchi K; Ishiuchi S; Yoshimoto Y; Yamada S; Nobusawa S; Ikota H; Hirato J; Yokoo H
Neuropathology; 2017 Aug; 37(4):351-357. PubMed ID: 28185325
[TBL] [Abstract][Full Text] [Related]
35. Molecular features and clinical outcomes in surgically treated low-grade diffuse gliomas in patients over the age of 60.
Morshed RA; Han SJ; Hervey-Jumper SL; Pekmezci M; Troncon I; Chang SM; Butowski NA; Berger MS
J Neurooncol; 2019 Jan; 141(2):383-391. PubMed ID: 30498891
[TBL] [Abstract][Full Text] [Related]
36. Ultrastructural pathology of glial brain tumors revisited: a review.
Liberski PP; Kordek R
Ultrastruct Pathol; 1997; 21(1):1-31. PubMed ID: 9029763
[TBL] [Abstract][Full Text] [Related]
37. BRAF V600E mutations are frequent in dysembryoplastic neuroepithelial tumors and subependymal giant cell astrocytomas.
Lee D; Cho YH; Kang SY; Yoon N; Sung CO; Suh YL
J Surg Oncol; 2015 Mar; 111(3):359-64. PubMed ID: 25346165
[TBL] [Abstract][Full Text] [Related]
38. The Role of Molecular Diagnostics in the Management of Patients with Gliomas.
Wirsching HG; Weller M
Curr Treat Options Oncol; 2016 Oct; 17(10):51. PubMed ID: 27501915
[TBL] [Abstract][Full Text] [Related]
39. Role of a Promoter Mutation in TERT in Malignant Transformation of Pleomorphic Xanthoastrocytoma.
Hosono J; Nitta M; Masui K; Maruyama T; Komori T; Yokoo H; Saito T; Muragaki Y; Kawamata T
World Neurosurg; 2019 Jun; 126():624-630. PubMed ID: 30599247
[TBL] [Abstract][Full Text] [Related]
40. Dysembryoplastic neuroepithelial tumor originally diagnosed as astrocytoma and oligodendroglioma.
Dozza DC; Rodrigues FF; Chimelli L
Arq Neuropsiquiatr; 2012 Sep; 70(9):710-4. PubMed ID: 22990729
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
